DJ Abivax postpones the publication of its 2023 Universal Registration Document
ABIVAX Abivax postpones the publication of its 2023 Universal Registration Document 28-Apr-2023 / 19:00 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
Abivax postpones the publication of its 2023 Universal Registration Document PARIS, France, April 28, 2023 - 7:00 p.m. (CEST) - Abivax (Euronext Paris: FR0012333284 - ABVX) (the "Company"), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, postpones the publication of its 2023 Universal Registration Document for technical reasons related, in particular, to the inclusion of financial statements for the years 2021 and 2022, prepared for the first time both under French Gaaps and IFRS standards.
Abivax will communicate on the new expected publication date in due time.
*****
About Abivax (www.abivax.com)
Abivax is a Phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.
Contacts
Abivax Investors Press Relations & Investors Europe Communications LifeSci Advisors MC Services AG Regina Jehle Ligia Vela-Reid Anne Hennecke regina.jehle@abivax.com lvela-reid@lifesciadvisors.com anne.hennecke@mc-services.eu +33 6 24 50 69 63 +44 7413 825310 +49 211 529 252 22 Public Relations France Public Relations France Public Relations USA Actifin Primatice Rooney Partners LLC Ghislaine Gasparetto Thomas Roborel de Climens Jeanene Timberlake ggasparetto@actifin.fr thomasdeclimens@primatice.com jtimberlake@rooneypartners.com +33 6 21 10 49 24 +33 6 78 12 97 95 +1 646 770 8858
DISCLAIMER
This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although Abivax' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document d'Enregistrement Universel). These risks, contingencies and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.
-----------------------------------------------------------------------------------------------------------------------
Regulatory filing PDF file File: 20230428_PR_Abivax_Publication URD postponed
=----------------------------------------------------
Language: English
Company: ABIVAX
5, Rue de La Baume
75008 Paris
France
E-mail: info@abivax.de
Internet: www.abivax.de
ISIN: FR0012333284
Euronext Ticker: ABVX
AMF Category: Inside information / Other releases
EQS News ID: 1621135
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
1621135 28-Apr-2023 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1621135&application_name=news
(END) Dow Jones Newswires
April 28, 2023 13:00 ET (17:00 GMT)
